# Klemens Raile

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 76 papers | 2,397 citations | 25 h-index | 48 g-index |
| 92 ext. papers | 2,913 ext. citations | 6.5 avg, IF | 4.33 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 76 | IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. *New England Journal of Medicine*, **2003**, 349, 2211-22 | 59.2 | 475 |
| 75 | Diabetic nephropathy in 27,805 children, adolescents, and adults with type 1 diabetes: effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex. *Diabetes Care*, **2007**, 30, 2523-8 | 14.6 | 181 |
| 74 | Recessive mutations in the INS gene result in neonatal diabetes through reduced insulin biosynthesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 3105-10 | 11.5 | 149 |
| 73 | ISPAD Clinical Practice Consensus Guidelines 2018: The diagnosis and management of monogenic diabetes in children and adolescents. *Pediatric Diabetes*, **2018**, 19 Suppl 27, 47-63 | 3.6 | 136 |
| 72 | Insulin allergy: clinical manifestations and management strategies. *Allergy: European Journal of Allergy and Clinical Immunology*, **2008**, 63, 148-55 | 9.3 | 100 |
| 71 | Diabetic retinopathy in type 1 diabetes-a contemporary analysis of 8,784 patients. *Diabetologia*, **2011**, 54, 1977-84 | 10.3 | 95 |
| 70 | Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study. *Lancet Diabetes and Endocrinology,the*, **2018**, 6, 637-646 | 18.1 | 77 |
| 69 | Entities and frequency of neonatal diabetes: data from the diabetes documentation and quality management system (DPV). *Diabetic Medicine*, **2010**, 27, 709-12 | 3.5 | 63 |
| 68 | Expanded clinical spectrum in hepatocyte nuclear factor 1b-maturity-onset diabetes of the young. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 2658-64 | 5.6 | 60 |
| 67 | Early manifestation of type 1 diabetes in children is a risk factor for changed bone geometry: data using peripheral quantitative computed tomography. *Pediatrics*, **2006**, 118, e627-34 | 7.4 | 58 |
| 66 | Insulin antibodies are associated with lipoatrophy but also with lipohypertrophy in children and adolescents with type 1 diabetes. *Experimental and Clinical Endocrinology and Diabetes*, **2001**, 109, 393-6 | 2.3 | 53 |
| 65 | Discontinuation of insulin pump treatment in children, adolescents, and young adults. A multicenter analysis based on the DPV database in Germany and Austria. *Pediatric Diabetes*, **2010**, 11, 116-21 | 3.6 | 51 |
| 64 | Associations between media consumption habits, physical activity, socioeconomic status, and glycemic control in children, adolescents, and young adults with type 1 diabetes. *Diabetes Care*, **2011**, 34, 2356-9 | 14.6 | 50 |
| 63 | Delayed pubertal onset and development in German children and adolescents with type 1 diabetes: cross-sectional analysis of recent data from the DPV diabetes documentation and quality management system. *European Journal of Endocrinology*, **2007**, 157, 647-53 | 6.5 | 48 |
| 62 | Mutational spectrum of COH1 and clinical heterogeneity in Cohen syndrome. *Journal of Medical Genetics*, **2006**, 43, e22 | 5.8 | 44 |
| 61 | Real-World Use of Do-It-Yourself Artificial Pancreas Systems in Children and Adolescents With Type 1 Diabetes: Online Survey and Analysis of Self-Reported Clinical Outcomes. *JMIR MHealth and UHealth*, **2019**, 7, e14087 | 5.5 | 41 |
| 60 | Tracking of metabolic control from childhood to young adulthood in type 1 diabetes. *Journal of Pediatrics*, **2014**, 165, 956-61.e1-2 | 3.6 | 37 |

| | | | |
|---|---|---|---|
| 59 | Physical activity and competitive sports in children and adolescents with type 1 diabetes. *Diabetes Care*, **1999**, 22, 1904-5 | 14.6 | 37 |
| 58 | Long-term lanreotide treatment in six patients with congenital hyperinsulinism. *Hormone Research in Paediatrics*, **2012**, 78, 106-12 | 3.3 | 33 |
| 57 | Genetic and clinical characteristics of patients with HNF1A gene variations from the German-Austrian DPV database. *European Journal of Endocrinology*, **2011**, 164, 513-20 | 6.5 | 32 |
| 56 | Apoptosis: live or die--hard work either way!. *Hormone and Metabolic Research*, **2001**, 33, 511-9 | 3.1 | 31 |
| 55 | Daily insulin requirement of children and adolescents with type 1 diabetes: effect of age, gender, body mass index and mode of therapy. *European Journal of Endocrinology*, **2008**, 158, 543-9 | 6.5 | 30 |
| 54 | Recessive mutations in PCBD1 cause a new type of early-onset diabetes. *Diabetes*, **2014**, 63, 3557-64 | 0.9 | 29 |
| 53 | Virilising adrenocortical tumours in children. *European Journal of Pediatrics*, **2003**, 162, 623-8 | 4.1 | 27 |
| 52 | Diabetes caused by insulin gene (INS) deletion: clinical characteristics of homozygous and heterozygous individuals. *European Journal of Endocrinology*, **2011**, 165, 255-60 | 6.5 | 26 |
| 51 | Meglitinide analogues in adolescent patients with HNF1A-MODY (MODY 3). *Pediatrics*, **2014**, 133, e775-9 | 7.4 | 25 |
| 50 | Tracking and prediction of arterial blood pressure from childhood to young adulthood in 868 patients with type 1 diabetes: a multicenter longitudinal survey in Germany and Austria. *Diabetes Care*, **2008**, 31, 726-7 | 14.6 | 25 |
| 49 | A new heterozygous mutation of the FOXL2 gene is associated with a large ovarian cyst and ovarian dysfunction in an adolescent girl with blepharophimosis/ptosis/epicanthus inversus syndrome. *European Journal of Endocrinology*, **2005**, 153, 353-8 | 6.5 | 25 |
| 48 | Higher relative risk for multiple sclerosis in a pediatric and adolescent diabetic population: analysis from DPV database. *Diabetes Care*, **2014**, 37, 96-101 | 14.6 | 21 |
| 47 | Continuous glucose monitoring in children, adolescents, and adults with type 1 diabetes mellitus: analysis from the prospective DPV diabetes documentation and quality management system from Germany and Austria. *Pediatric Diabetes*, **2012**, 13, 12-4 | 3.6 | 21 |
| 46 | Diagnosis, Therapy and Follow-Up of Diabetes Mellitus in Children and Adolescents. *Experimental and Clinical Endocrinology and Diabetes*, **2019**, 127, S39-S72 | 2.3 | 20 |
| 45 | Frequency and Characteristics of MODY 1 (HNF4A Mutation) and MODY 5 (HNF1B Mutation): Analysis From the DPV Database. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 845-855 | 5.6 | 19 |
| 44 | Two novel GATA6 mutations cause childhood-onset diabetes mellitus, pancreas malformation and congenital heart disease. *Hormone Research in Paediatrics*, **2013**, 79, 250-6 | 3.3 | 18 |
| 43 | Protein phosphatase 1 (PP-1)-dependent inhibition of insulin secretion by leptin in INS-1 pancreatic β-cells and human pancreatic islets. *Endocrinology*, **2011**, 152, 1800-8 | 4.8 | 17 |
| 42 | Pulse pressure in children and adolescents with type 1 diabetes mellitus in Germany and Austria. *Pediatric Diabetes*, **2014**, 15, 236-43 | 3.6 | 16 |

| | | | |
|---|---|---|---|
| 41 | Natural course of untreated microalbuminuria in children and adolescents with type 1 diabetes and the importance of diabetes duration and immigrant status: longitudinal analysis from the prospective nationwide German and Austrian diabetes survey DPV. *European Journal of Endocrinology*, **2012**, 166, 493-501 | 6.5 | 15 |
| 40 | Polyoma virus-associated progressive multifocal leukoencephalopathy after renal transplantation: regression following withdrawal of mycophenolate mofetil. *Pediatric Transplantation*, **2011**, 15, E19-24 | 1.8 | 14 |
| 39 | Predicting the optimal basal insulin infusion pattern in children and adolescents on insulin pumps. *Diabetes Care*, **2013**, 36, 1507-11 | 14.6 | 13 |
| 38 | Evidence on User-Led Innovation in Diabetes Technology (The OPEN Project): Protocol for a Mixed Methods Study. *JMIR Research Protocols*, **2019**, 8, e15368 | 2 | 13 |
| 37 | Why #WeAreNotWaiting-Motivations and Self-Reported Outcomes Among Users of Open-source Automated Insulin Delivery Systems: Multinational Survey. *Journal of Medical Internet Research*, **2021**, 23, e25409 | 7.6 | 13 |
| 36 | deletion causes extensive vacuolation that consumes the insulin content of pancreatic □cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 19983-19988 | 11.5 | 12 |
| 35 | Investigation of Naturally Occurring Single-Nucleotide Variants in Human TAAR1. *Frontiers in Pharmacology*, **2017**, 8, 807 | 5.6 | 12 |
| 34 | Occurrence of giant focal forms of congenital hyperinsulinism with incorrect visualization by (18) F DOPA-PET/CT scanning. *Clinical Endocrinology*, **2014**, 81, 847-54 | 3.4 | 12 |
| 33 | Primary sulphonylurea therapy in a newborn with transient neonatal diabetes attributable to a paternal uniparental disomy 6q24 (UPD6). *Diabetes, Obesity and Metabolism*, **2018**, 20, 474-475 | 6.7 | 10 |
| 32 | Moderne Behandlungskonzepte f□ Kinder und Jugendliche mit Diabetes mellitus Typ 1. *Monatsschrift Fur Kinderheilkunde*, **2001**, 149, 650-659 | 0.2 | 8 |
| 31 | Open-source automated insulin delivery: international consensus statement and practical guidance for health-care professionals. *Lancet Diabetes and Endocrinology,the*, **2021**, | 18.1 | 8 |
| 30 | Incidence of COVID-19 and Risk of Diabetic Ketoacidosis in New-Onset Type 1 Diabetes. *Pediatrics*, **2021**, 148, | 7.4 | 8 |
| 29 | HNF1B abnormality (mature-onset diabetes of the young 5) in children and adolescents: high prevalence in autoantibody-negative type 1 diabetes with kidney defects. *Diabetes Care*, **2008**, 31, e83 | 14.6 | 7 |
| 28 | Pharmacoeconomics of obesity management in childhood and adolescence. *Expert Opinion on Pharmacotherapy*, **2003**, 4, 1471-7 | 4 | 7 |
| 27 | 117-LB: DIWHY: Factors Influencing Motivation, Barriers, and Duration of DIY Artificial Pancreas System Use among Real-World Users. *Diabetes*, **2019**, 68, 117-LB | 0.9 | 7 |
| 26 | Shaping Workflows in Digital and Remote Diabetes Care During the COVID-19 Pandemic via Service Design: Prospective, Longitudinal, Open-label Feasibility Trial. *JMIR MHealth and UHealth*, **2021**, 9, e24374 | 5.5 | 7 |
| 25 | Long-term Follow-up of Glycemic and Neurological Outcomes in an International Series of Patients With Sulfonylurea-Treated Permanent Neonatal Diabetes. *Diabetes Care*, **2021**, 44, 35-42 | 14.6 | 7 |
| 24 | HDAC4 mutations cause diabetes and induce □cell FoxO1 nuclear exclusion. *Molecular Genetics & Genomic Medicine*, **2019**, 7, e602 | 2.3 | 6 |

| | | | |
|---|---|---|---|
| 23 | Changes in pediatric diabetes care throughout a 30-yr period at one institution for pediatric diabetology in Germany. *Pediatric Diabetes*, **2002**, 3, 70-3 | 3.6 | 6 |
| 22 | Real-world evidence on clinical outcomes of people with type 1 diabetes using open-source and commercial automated insulin dosing systems: A systematic review. *Diabetic Medicine*, **2021**, e14741 | 3.5 | 4 |
| 21 | 78-LB: Detailing the Experiences of People with Diabetes Using Do-It-Yourself Artificial Pancreas Systems□Qualitative Analysis of Responses to Open-Ended Items in an International Survey. *Diabetes*, **2019**, 68, 78-LB | 0.9 | 4 |
| 20 | Open-Source Technology for Real-Time Continuous Glucose Monitoring in the Neonatal Intensive Care Unit: Case Study in a Neonate With Transient Congenital Hyperinsulinism. *Journal of Medical Internet Research*, **2020**, 22, e21770 | 7.6 | 3 |
| 19 | Comorbidity of inflammatory bowel disease in children and adolescents with type 1 diabetes. *Acta Paediatrica, International Journal of Paediatrics*, **2021**, 110, 1353-1358 | 3.1 | 3 |
| 18 | Asthma in children and adolescents with type 1 diabetes in Germany and Austria: Frequency and metabolic control. *Pediatric Diabetes*, **2018**, 19, 727-732 | 3.6 | 3 |
| 17 | Changes in HbA1c Between 2011 and 2017 in Germany/Austria, Sweden, and the United States: A Lifespan Perspective. *Diabetes Technology and Therapeutics*, **2021**, | 8.1 | 3 |
| 16 | Complications and Consequences **2005**, 10, 329-346 | | 1 |
| 15 | Evaluation of a rare glucose-dependent insulinotropic polypeptide receptor variant in a patient with diabetes. *Diabetes, Obesity and Metabolism*, **2019**, 21, 1168-1176 | 6.7 | 1 |
| 14 | Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter. *Diabetologe*, **2021**, 17, 557-584 | 0.2 | 1 |
| 13 | Autoimmunthyreopathien bei Kindern und Jugendlichen mit Typ-1-Diabetes H□figkeit und sinnvolles Screening. *Monatsschrift Fur Kinderheilkunde*, **2002**, 150, 619-624 | 0.2 | 0 |
| 12 | □iopathogenese des Diabetes mellitus Typ 1. *Monatsschrift Fur Kinderheilkunde*, **2001**, 149, 641-649 | 0.2 | 0 |
| 11 | Size matters: Influence of center size on quality of diabetes control in children and adolescents with type 1 diabetes-A longitudinal analysis of the DPV cohort. *Pediatric Diabetes*, **2021**, 23, 64 | 3.6 | 0 |
| 10 | Variability of Glycemic Outcomes and Insulin Requirements Throughout the Menstrual Cycle: A Qualitative Study on Women With Type 1 Diabetes Using an Open-Source Automated Insulin Delivery System.. *Journal of Diabetes Science and Technology*, **2022**, 19322968221080199 | 4.1 | 0 |
| 9 | H□figkeitsgipfel im Vorschulalter und in der Pubert□ - Behandlung des Diabetes mellitus bei Kindern und Jugendlichen. *Notfall & Hausarztmedizin (Notfallmedizin)*, **2006**, 32, 608-616 | | |
| 8 | Early glibenclamide treatment in a clinical newborn with KCNJ11 gene mutation. *Diabetes Care*, **2007**, 30, e104 | 14.6 | |
| 7 | Special diet in type 1 diabetes: do gender and BMI-SDS differ?. *Child and Adolescent Obesity*, **2021**, 4, 131-147 | 1.1 | |
| 6 | Der Stoffwechselnotfall **2007**, 337-351 | | |

| | | |
|---|---|---|
| 5 | Erkrankungen der endokrinen Drüsen inkl. Diabetes und Wachstumsstörungen **2007**, 535-593 | |
| 4 | Diabetesformen bei Kindern und Jugendlichen. *Springer Reference Medizin*, **2018**, 1-12 | 0 |
| 3 | Diabetesformen bei Kindern und Jugendlichen. *Springer Reference Medizin*, **2020**, 159-170 | 0 |
| 2 | Telemedizin in der Kinderdiabetologie. *Diabetologe*, **2021**, 17, 638-646 | 0.2 |
| 1 | Physical and Reported Subjective Health Status in 222 Individuals with XY Disorder of Sex Development. *Journal of the Endocrine Society*, **2021**, 5, bvab103 | 0.4 |